Brain

1. RODGERS J, Friede T, Vonberg FW, Constantinescu CS, et al
   The impact of smoking cessation on multiple sclerosis disease progression.
   Brain. 2021 Oct 8. pii: 6384574. doi: 10.1093.
   

   >> Share

   
   

   
   J Clin Invest

2. SINGH AK, Netea MG, Bishai WR
   BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.
   J Clin Invest. 2021;131.
   

   >> Share

   
   

   
   J Neurol

3. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
   Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
   J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
   

   >> Share

   
   

   
   J Neurol Sci

4. PLOWMAN RS, Varma H
   Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
   J Neurol Sci. 2021;428:117591.
   

   >> Share

   
   
5. XIE JS, Jeeva-Patel T, Margolin E
   Balo's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.
   J Neurol Sci. 2021;428:117570.
   

   >> Share

   
   

   
   Mult Scler

6. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
   Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
   Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
   

   >> Share

   
   
7. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
   Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
   Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
   

   >> Share

   
   
8. BOSMA AR, Murley C, Aspling J, Hillert J, et al
   Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
   Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
   

   >> Share

   
   
9. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
   Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
   Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
   

   >> Share

   
   
10. VILLOSLADA P
    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
    

    >> Share

    
    
11. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    

    >> Share

    
    
12. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    

    >> Share

    
    

    
    Neurology

13. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    

    >> Share

    
    
14. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    

    >> Share

    
    
15. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    

    >> Share

    
    
16. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    

    >> Share

    
    
17. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    

    >> Share

    
    

    
    Rev Neurol (Paris)

18. MICHEL M, Le Page E, Laplaud DA, Wardi R, et al
    Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
    Rev Neurol (Paris). 2021 Sep 28. pii: S0035-3787(21)00664.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share